Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
424.00    -15.00 (-3.42%)
Bid:
426.00
Ask:
430.00
Spread: 4.00 (0.939%)
Market Cap: £208.53m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Third Quarter Trading Update

1 Nov 2017 07:00

RNS Number : 1767V
Zotefoams PLC
01 November 2017
 

Zotefoams plc

("Zotefoams" or the "Company" or "Group")

 

Trading Update

 

1st November 2017 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the third quarter ended 30 September 2017.

 

Zotefoams is pleased to report continued strong trading during the third quarter, maintaining the momentum of organic sales growth experienced in the first half of the year.

 

· Full year revenues expected to be ahead of market expectations

 

· Adjusted profit before tax and exceptional items for the year ending 31 December 2017 expected to be at the top end of the range of market expectations

 

· Group revenue 22% ahead for the third quarter against the comparative period

 

· Group revenue 24% ahead for the first nine months against the comparative period

 

In constant currency sales grew 16% in the third quarter following a 14% increase for the first six months of the year. The year-to-date growth has been delivered across all business units, with particularly strong growth in High-Performance Products, during the third quarter.

 

Management continues to invest in its strong portfolio of growth prospects and to manage the higher growth rates of early stage opportunities. The order book for the fourth quarter gives confidence that the Company will exceed market expectations for Group revenue and therefore, at current foreign exchange rates, the Board expects adjusted profit before tax and exceptional items for the year ending 31 December 2017 to be at the top end of the range of market expectations.

 

 

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"We are delighted with the strong organic growth achieved across all business units during the third quarter of 2017. Our ambition is to establish ourselves as the world leader in cellular materials technology in our chosen markets. To achieve this ambition, we are investing significantly in new equipment and enhanced business capability. The Board is confident of another year of positive progress and about the long-term prospects for the business."

 

 

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory

+44 (0) 203 053 8671

Graham Herring

Miles Nolan

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces and sells lightweight AZOTE® polyolefin and ZOTEK® high-performance foams for diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®).

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUARWRBBAROAA
Date   Source Headline
4th Aug 20097:00 amRNSHalf Yearly Report
20th Jul 20091:42 pmRNSHolding(s) in Company
3rd Jul 20097:00 amRNSTrading Statement
17th Jun 20095:33 pmRNSHolding(s) in Company
5th Jun 200912:23 pmRNSDirector/PDMR Shareholding
19th May 200910:30 amRNSAnnual Information Update
12th May 200910:30 amRNSVoting Rights and Capital
7th May 20097:00 amRNSAGM Statement
7th Apr 200910:51 amRNSNotice of AGM
26th Mar 20097:00 amRNSAdditional Listing
18th Mar 20091:50 pmRNSDirector/PDMR Shareholding
16th Mar 20095:19 pmRNSDirector/PDMR Shareholding
10th Mar 20097:00 amRNSFinal Results
22nd Jan 200911:36 amRNSHolding(s) in Company
5th Jan 20091:19 pmRNSVoting Rights and Capital
19th Dec 20087:00 amRNSTrading Statement
12th Dec 200811:04 amRNSDirector/PDMR Shareholding
11th Dec 20082:20 pmRNSHolding(s) in Company
3rd Nov 20087:00 amRNSInterim Management Statement
30th Oct 20082:25 pmRNSAdditional Listing
14th Aug 20087:00 amRNSDirector/PDMR Shareholding
5th Aug 20087:00 amRNSInterim Results
9th Jul 20089:11 amRNSAcquires Stake
1st Jul 20087:00 amRNSTrading Update
5th Jun 20089:37 amRNSVoting rights and capital
23rd May 20085:38 pmRNSAnnual Information Update
8th May 20087:01 amRNSAGM Statement
14th Apr 20087:00 amRNSBlocklisting Interim Review
8th Apr 20086:07 pmRNSAdditional Listing
8th Apr 20088:18 amRNSNotice of AGM
25th Mar 20082:46 pmRNSDirector/PDMR Shareholding
4th Mar 20087:01 amRNSFinal Results
3rd Mar 20087:00 amRNSCustomer Achievement
1st Feb 20081:46 pmRNSTotal Voting Rights
21st Dec 20072:48 pmRNSDirectors' Shareholdings
26th Nov 200710:04 amRNSAdditional Listing
12th Nov 20077:01 amRNSDirector/PDMR Shareholding
7th Nov 20078:45 amRNSDirectors' Shareholdings
30th Oct 20072:55 pmRNSHolding in Company
19th Oct 20077:01 amRNSProduct Achievement
17th Oct 20079:32 amRNSBlocklisting Interim Review
5th Sep 200712:29 pmRNSHolding(s) in Company
28th Aug 20077:02 amRNSMarketing Alliance
7th Aug 20077:00 amRNSInterim Results
30th Jul 20074:45 pmRNSVoting rights & capital
12th Jul 20074:02 pmRNSDirectorate Change
29th Jun 200711:04 amRNSTrading Update
28th Jun 20072:23 pmRNSHolding(s) in Company
21st May 200712:03 pmRNSAnnual Information Update
17th May 20079:14 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.